|The following article features coverage from the 2021 ASCO Quality Care Symposium. Click here to read more of Oncology Nurse Advisor‘s conference coverage.|
Use of anti-infective prophylaxis (AIP) in patients with non-Hodgkin lymphoma (NHL) differed significantly across US community settings. These findings were presented during the 2021 ASCO Quality Care Symposium.
Although infection complications lead to morbidity and mortality for patients with NHL, evidence to guide which clinical situations should prompt AIP is limited.
Researchers from Yale School of Medicine sourced data from the nationwide Flatiron Health database, which collects data from approximately 280 cancer centers in the United States. Patients with NHL were assessed for administration of AIP, defined as anti-viral and/or Pneumocystis jiroveci pneumonia (PJP) prophylaxis, within 14 days of NHL treatment initiation.
This study included 3590 patients receiving ibrutinib for CLL/SLL; 3142 receiving rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, prednisolone (R-CHOP) for DLBCL; and 2180 receiving bendamustine and rituximab (BR) for CLL/SLL, median ages were 72, 69, and 69 years, respectively.
More patients receiving BR were given AIP (any: 16.8%; antiviral: 15.6%; PJP: 7.3%), followed by R-CHOP (any: 10.5%; antiviral: 7.6%; PJP: 5.6%) and ibrutinib (any: 6.4%; antiviral: 5.6%; PJP: 2.6%).
AIP was more frequently given to patients undergoing proteosome inhibitor therapy for multiple myeloma, those living in the Midwest, and patients with more recent treatment initiation.
These data suggested there was generally low AIP utilization during NHL therapy and that patient characteristics did not seem to predict whether a patient would receive AIP. Additional study is needed to assess best practices for AIP use such that complications from infections may be reduced in patients with NHL.
Disclosure: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for the full list of authors’ disclosures.
Read more of Oncology Nurse Advisor’s coverage of the 2021 ASCO Quality Care Symposium by visiting the conference page.
Di M, Soulos PR, Huntington SF. Primary anti-infective prophylaxis during routine treatment of lymphoma in the United States: a large real-world cohort analysis. J Clin Oncol. 2021;39(suppl 28):abstr 268. doi:10.1200/JCO.2020.39.28_suppl.268